Core Points - A lawsuit is currently pending against Elevance Health, Inc. (NYSE: ELV) regarding alleged violations of securities laws [2] - The plaintiff claims that Elevance misrepresented its monitoring of cost trends and the adequacy of premium rates negotiated with states, particularly concerning patients remaining on Medicaid [2] - An amended complaint was filed on October 7, 2025, urging investors who purchased shares prior to April 2024 to contact the Shareholders Foundation for further information [3] Summary by Sections Lawsuit Details - The lawsuit alleges that Elevance Health, Inc. misled investors about its financial guidance and the management of costs associated with Medicaid patients [2] - It is claimed that sicker patients with higher acuity remained on Medicaid, leading to increased per-patient costs that were not adequately reflected in Elevance's financial forecasts [2] Investor Information - Investors who purchased shares of Elevance Health, Inc. before April 2024 and still hold them are encouraged to reach out to the Shareholders Foundation for options regarding the lawsuit [1][3] - The Shareholders Foundation provides services related to shareholder issues and informs investors about securities class actions and legal news [3]

Core Viewpoint - Elevance Health is set to release its third quarter 2025 financial results on October 21, 2025, at 6:00 a.m. EDT, followed by a management conference call at 8:30 a.m. EDT to discuss the results and outlook [1] Financial Results Release - The financial results will be available on October 21, 2025, at 6:00 a.m. EDT [1] - A conference call will take place at 8:30 a.m. EDT on the same day to review the results and future outlook [1] Access Information - Participants are advised to access the conference call at least 15 minutes prior to its start [1] - Domestic access number: 888-947-9963 with access code 3972058 [1] - International access number: 312-470-0178 with access code 3972058 [1]

Core Insights - The article emphasizes the importance of understanding macro trends and their influence on asset prices and investor behavior, particularly in the context of equity analysis and research [1]. Group 1: Professional Background - The expert has over 10 years of experience in asset management, focusing on equity analysis, macroeconomics, and risk-managed portfolio construction [1]. - The professional background includes advising on and implementing multi-asset strategies, with a strong emphasis on equities and derivatives [1]. Group 2: Investment Philosophy - The goal of sharing insights is to make investing accessible, inspiring, and empowering for fellow investors [1]. - The expert encourages building confidence in long-term investing through shared knowledge and collaboration [1]. Group 3: Market Analysis Focus - The analysis includes close monitoring of EU and US central bank policies, sector rotation, and sentiment dynamics to construct actionable investment strategies [1]. - The expert has navigated various market conditions over the past decade, indicating a robust understanding of market dynamics [1].

Core Insights - Elevance Health, Inc. is restructuring its Medicare strategy by exiting underperforming Medicare Advantage markets and the standalone Part D segment to protect profitability and enhance competitiveness [1][8] - The company is focusing resources on Medicare Advantage HMO and dual-special needs plans (D-SNPs), which yield stronger margins and consistent enrollment growth [2][8] - The exit will affect approximately 150,000 of Elevance's 2.3 million Medicare Advantage members, reflecting a broader industry trend of insurers recalibrating to safeguard margins amid rising medical costs [3][5] Financial Outlook - Elevance has revised its 2025 adjusted EPS forecast to about $30, down from a previous range of $34.15–$34.85, in response to increasing medical costs [4][8] - The Zacks Consensus Estimate for Elevance's 2025 earnings is projected at $29.88 per share, indicating a 9.6% decline from the previous year [11] - The company's trailing 12-month return on capital is 10.4%, significantly above the industry average of 7.4%, suggesting it can navigate challenges effectively [2] Market Position - Elevance's exit from the standalone Part D segment will reduce choices for beneficiaries, as it ranks as the sixth-largest provider in this space [5] - Other major players like UnitedHealth Group and Molina Healthcare have also adjusted their forecasts for 2025, indicating a trend across the industry [4] - Elevance's stock has declined by 14.6% year-to-date, compared to a 2.9% decline in the industry [7] Valuation Metrics - Elevance trades at a forward price-to-earnings ratio of 10.06, lower than the industry average of 14.90, and currently holds a Value Score of A [10]

Group 1 - The health insurance sector is currently facing historic pressure, which may present generational buying opportunities for patient investors [1] - Most insurers have been caught off guard by recent challenges in the market [1]

Core Insights - Elevance Health, Inc. is transitioning from a traditional health insurer to a comprehensive healthcare solutions provider, focusing on strategic partnerships and integrated care models [1][8] - The company is expanding into primary care, digital health, and pharmacy services to offer holistic health solutions that address broader health determinants [2][8] - Elevance Health's initiatives aim to reduce hospitalizations and enhance care accessibility through AI-enabled platforms and telehealth services [3][4] Membership and Revenue Growth - Medicare Advantage memberships increased by 11% year-over-year in Q2 2025, while individual membership grew by 5.2% [4][8] - Total revenues rose by 13.4% year-over-year in the same quarter [4][8] Competitive Landscape - Competitors like UnitedHealth Group and Humana are also focusing on value-based care, with UnitedHealth's Optum division reporting a 5.8% revenue growth in the first half of 2025 [5] - Humana's total adjusted revenues increased by 9.9% year-over-year in the first half of 2025 [6] Valuation and Earnings Estimates - Elevance Health's shares have declined by 14.9% year-to-date, contrasting with a 0.2% decline in the industry [7] - The company trades at a forward price-to-earnings ratio of 9.88, below the industry average of 15.23 [9] - The Zacks Consensus Estimate for Elevance Health's 2025 earnings is $29.88 per share, indicating a 9.6% decline from the previous year [11]

Core Insights - Elevance Health, Inc. (ELV) is focusing on expanding its value-based care model, which emphasizes patient outcomes rather than the quantity of care provided [1][2] - The company is particularly enhancing its value-based care offerings in behavioral health and oncology through its Carelon business, which integrates various healthcare services [2][8] Company Performance - Elevance Health's care delivery services target chronic and complex populations, providing tailored care both at home and virtually [3] - The acquisition of CareBridge in 2024 allows the company to offer virtual care to Medicaid and Medicare patients, enhancing its management of home and community-based services [3] - In the last reported quarter, Medicare Advantage memberships increased by 11% year over year, while total revenues rose by 13.4% [4][8] Competitive Landscape - Competitors such as UnitedHealth Group and Humana are also expanding in the value-based care space, with UnitedHealth's Optum division reporting a 5.8% year-over-year revenue growth in the first half of 2025 [5] - Humana's CenterWell business saw an 8.9% year-over-year revenue increase in the same period [6] Valuation and Estimates - Elevance Health's shares have decreased by 14.1% year-to-date, contrasting with a 0.7% decline in the industry [7] - The company trades at a forward price-to-earnings ratio of 9.62, significantly lower than the industry average of 15.16, and currently holds a Value Score of A [10] - The Zacks Consensus Estimate for Elevance Health's 2025 earnings is $30.15 per share, indicating an 8.8% decline from the previous year [11]

Core Insights - The author has extensive experience in executive management, particularly in insurance/reinsurance and the Asia Pacific markets, with a focus on climate change and ESG [1] Group 1 - The author holds an honours degree in economics and politics, emphasizing economic development [1] - The author has 36 years of experience in executive management, providing a deep understanding of relevant markets [1] - The author invests personally, indicating a vested interest in the analysis presented [1]

Core Insights - Elevance Health, Inc. faced a legal setback as a federal judge dismissed its challenge against the Medicare Advantage star ratings set by the Centers for Medicare & Medicaid Services (CMS) [1][4] - The dismissal means Elevance will forgo an estimated $375 million in bonus payments for 2025 due to a rating that was rounded down from 3.749565 stars to 3.5 stars, just below the four-star threshold [2][8] - The outcome emphasizes the regulatory risks in the Medicare Advantage sector, potentially influencing operational strategies for Elevance and its peers [4] Financial Implications - Elevance's rating downgrade will result in a significant loss of bonus payments, estimated at $375 million for 2025 [2][8] - The company's shares have declined by 16.1% year-to-date, contrasting with the industry's growth of 0.2% [7] Industry Context - CMS issues annual star ratings that are critical for determining federal bonus payments and consumer enrollment in Medicare Advantage plans [3][8] - Other insurers, such as Centene Corporation and Humana Inc., have also faced challenges related to rating methodology changes, with varying outcomes [5][6] Valuation Metrics - Elevance currently trades at a forward price-to-earnings ratio of 9.72, significantly lower than the industry average of 15.25 [10] - The Zacks Consensus Estimate for Elevance's 2025 earnings is $30.15 per share, reflecting an 8.8% decline from the previous year [11]

Core Insights - Elevance Health, Inc. (ELV) is integrating Food as Medicine into its primary care model through a partnership with the National Association of Community Health Centers (NACHC) to enhance treatment plans with nutrition [1][9] - The initiative aims to address food and nutrition insecurities while improving chronic disease management and preventive health outcomes for approximately 34 million Americans served by Community Health Centers (CHCs) [3][9] - Elevance Health's individual medical membership increased by 5.2% year over year in Q2 2025, reaching 1.3 million, with expectations of a 0.7% rise in 2025 [4] Company Strategy - The collaboration will train primary care teams at CHCs to connect Medicaid patients with personalized nutrition support, including medically tailored meals and lifestyle interventions [2][9] - The goal is to establish a scalable Nutrition Center of Excellence that could serve as a national model for food-based clinical care [4][9] Competitor Analysis - Centene Corporation (CNC) reported a 6.2% year-over-year growth in high-acuity Medicaid membership, totaling around 28 million members as of June 30, 2025, with total revenues increasing by 22.4% [5] - Cigna Group (CI) experienced a 3.2% year-over-year growth in international health customers, with total medical customers around 18 million and total revenues rising by 11% [6] Financial Performance - Elevance Health's stock has declined by 16.1% year-to-date, contrasting with a 1% decline in the industry [7] - The company trades at a forward price-to-earnings ratio of 9.62, significantly lower than the industry average of 15.08, and currently holds a Value Score of A [10] - The Zacks Consensus Estimate for Elevance Health's 2025 earnings is $30.59 per share, indicating a 7.4% decline from the previous year [11]